Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 279 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... July 5, 2024 Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases... June 13, 2023 Got the COVID Blues? August 12, 2020 Mediterranean Diet Associated with a Higher Probability of Response in Patients... February 28, 2023 Load more HOT NEWS A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Tackling under-representation of Black data scientists in cancer research No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax...
